The Optimal Treatment for Treatment-resistant Schizophrenia
To explore the curative effect and safety of Risperidone，aripiprazole，sodium valproate，modified electroconvulsive therapy(MECT), or Magnetic seizure therapy(MST) with Clozapine in the treatment of treatment-resistant schizophrenia， and to provide the basis for clinical medication.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
150
Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
DTliu
Shanghai, China
RECRUITINGChange from baseline in Positive and Negative Syndrome Scale [PANSS]
Time frame: At baseline, 4th week, 8th week,12th week
Change from baseline in clinical global impression [CGI]
Time frame: At baseline, 4th week, 8th week,12th week
Change from baseline in Simpson-Angus Scale [SAS]
Time frame: At baseline, 4th week, 8th week,12th week
Change from baseline in Abnormal Involuntary Movement Scale[AIMS]
Time frame: At baseline, 4th week, 8th week,12th week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
clozapine may be used in the treatment of treatment-resistant schizophrenia